The patent-pending technology employed by EteRNAVax was conceived and developed at the Georgia Institute of Technology by Prof. Marcus Cicerone and Dr. Sunil Yadava.
Prof. Cicerone has been contributing pioneering research in the dynamics of liquids and glass for the past 30 years. Initially this work was focused on fundamental studies, but in 1996 he began to apply results of the fundamental work to preservation of biologically active materials. In 2004 he introduced the idea that picosecond-timescale motion was predictive of shelf-life stability in solid-form biopharmaceuticals. Since then, he has introduced approaches for rapidly estimating and optimizing solid formulation stability, and incorporating labile proteins into synthetic polymer constructs with essentially no loss of protein activity. With Dr. Yadave, he has now developed a similar technology for nucleic acid stabilization and delivery.
Dr. Yadava is an expert in the development of novel nanoplatforms for drug and gene delivery. With a successful track record in developing controlled-release nanoparticles and nanocapsules for drug and mRNA delivery and various biomedical applications. He co-invented the formulation and process used by EteRNAVax for ambient stabilization and delivery of mRNA for use in laboratory transfection, vaccines, and targeted delivery of mRNA and cancer immunotherapy through mRNA/nanomedicines.
Innovative mRNA Delivery and Transfection Solutions
Cutting-Edge Technology
Our technology ensures room temperature stability without sacraficing efficacy, revolutionizing vaccine and drug delivery for affordability and accessibility.
Our Mission
Our dedicated team focuses on groundbreaking research, developing ambient-stable mRNA delivery that meets the highest standards of quality and safety.
Research and Development
We are committed to advancing healthcare through innovative mRNA technologies, ensuring safe and effective vaccines for all.
What are mRNA vaccines?
mRNA vaccines are a new type of vaccine that use messenger RNA to instruct cells to produce a protein that triggers an immune response. This technology allows for rapid development and adaptability against various pathogens.
How does EteRNAVax ensure vaccine stability?
EteRNAVax employs innovative formulation techniques to create ambient-stable mRNA vaccines. These methods enhance the stability of the mRNA, allowing it to remain effective without the need for cold storage, thus facilitating easier distribution and access.
What markets does EteRNAVax serve?
EteRNAVax serves a variety of markets including healthcare, pharmaceuticals, and biotechnology. Our focus is on providing solutions that address public health needs, particularly in vaccine development and delivery, ensuring that our products meet the highest standards of efficacy and safety.
How can I invest in EteRNAVax?
Interested investors can reach out through our Investors & Partners page for detailed information on investment opportunities. We welcome partnerships that align with our mission to innovate in the field of mRNA vaccines and contribute to global health solutions.